Sensorium Therapeutics Announces Appointment of Veteran Biotech Executive Alexandra Glucksmann, Ph.D., as CEO as the Company Progresses Toward the Clinic
Glucksmann succeeds current Sensorium CEO and Co-Founder Dick Simon, who will transition to an advisory role and continue to serve on the Board of Directors
The company announces a $3 million National Institutes of Health/National Institute on Aging gra... Biopharmaceuticals, Personnel Sensorium Therapeutics, anxiety, depression
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Anxiety | Biotechnology | Depression | National Institutes of Health (NIH) | Pharmaceuticals